S Phillips1,2,3, A M Cornall4,5, D A Machalek4,5, S M Garland4,5,6, D Bateson7, M Garefalakis8, S N Tabrizi4,5,6. 1. Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia. sam.phillips@mcri.edu.au. 2. Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Bio 21 Institute, Parkville, 3052, Australia. sam.phillips@mcri.edu.au. 3. Murdoch Childrens Research Institute, Parkville, Victoria, 3052, Australia. sam.phillips@mcri.edu.au. 4. Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia. 5. Murdoch Childrens Research Institute, Parkville, Victoria, 3052, Australia. 6. Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia. 7. Family Planning New South Wales, Ashfield, NSW, Australia. 8. Family Planning Western Australia, Northbridge, WA, Australia.
Abstract
UNLABELLED: Roche Amplicor HPV (AMP) had previously been used for detection of high-risk human papillomavirus (HR-HPV) in epidemiological and clinical studies. As this assay is no longer available, we compared its performance using PreservCyt samples from women aged of 18-24 years attending for routine cervical cytology screening to Roche Cobas® 4800 (Cobas) to determine if subsequent studies could continue using the Cobas assay. Overall 507 samples were tested on Cobas and compared to previous AMP results, with discrepant samples tested on Roche Linear Array. RESULTS: Overall, agreement between the Cobas and AMP for the presence of HR HPV types was very high (κ = 0.81) (95 % CI: 0.76 - 0.87) with percentage agreement of 91.57 %. Cobas is comparable to AMP for the detection of HR-HPV types in a community recruited cohort of healthy women.
UNLABELLED: Roche Amplicor HPV (AMP) had previously been used for detection of high-risk human papillomavirus (HR-HPV) in epidemiological and clinical studies. As this assay is no longer available, we compared its performance using PreservCyt samples from women aged of 18-24 years attending for routine cervical cytology screening to Roche Cobas® 4800 (Cobas) to determine if subsequent studies could continue using the Cobas assay. Overall 507 samples were tested on Cobas and compared to previous AMP results, with discrepant samples tested on Roche Linear Array. RESULTS: Overall, agreement between the Cobas and AMP for the presence of HR HPV types was very high (κ = 0.81) (95 % CI: 0.76 - 0.87) with percentage agreement of 91.57 %. Cobas is comparable to AMP for the detection of HR-HPV types in a community recruited cohort of healthy women.
Authors: Julia C Gage; Mark Sadorra; Brandon J Lamere; Randi Kail; Carrie Aldrich; Walter Kinney; Barbara Fetterman; Thomas Lorey; Mark Schiffman; Philip E Castle Journal: J Clin Microbiol Date: 2011-11-09 Impact factor: 5.948
Authors: Sepehr N Tabrizi; Matthew P Stevens; Zaheer A Khan; Conan Chow; Martin A Devitt; Suzanne M Garland Journal: J Clin Microbiol Date: 2012-05-30 Impact factor: 5.948
Authors: Thomas C Wright; Mark H Stoler; Catherine M Behrens; Raymond Apple; Toniann Derion; Teresa L Wright Journal: Am J Obstet Gynecol Date: 2011-07-22 Impact factor: 8.661
Authors: Mark H Stoler; Thomas C Wright; Abha Sharma; Guili Zhang; Raymond Apple; Teresa L Wright; Catherine M Behrens Journal: Am J Clin Pathol Date: 2012-02 Impact factor: 2.493
Authors: Samuel Phillips; Suzanne M Garland; Jeffery H Tan; Michael A Quinn; Sepehr N Tabrizi Journal: J Clin Virol Date: 2014-11-18 Impact factor: 3.168
Authors: Matthew P Stevens; Suzanne M Garland; Elice Rudland; Jeffrey Tan; Michael A Quinn; Sepehr N Tabrizi Journal: J Clin Microbiol Date: 2007-05-09 Impact factor: 5.948
Authors: Sepehr N Tabrizi; Julia M L Brotherton; John M Kaldor; S Rachel Skinner; Bette Liu; Deborah Bateson; Kathleen McNamee; Maria Garefalakis; Samuel Phillips; Eleanor Cummins; Michael Malloy; Suzanne M Garland Journal: Lancet Infect Dis Date: 2014-08-05 Impact factor: 25.071
Authors: A M Cornall; M Poljak; S M Garland; S Phillips; J H Tan; D A Machalek; M A Quinn; S N Tabrizi Journal: Eur J Clin Microbiol Infect Dis Date: 2016-11-08 Impact factor: 3.267
Authors: M Jesus Purriños-Hermida; María Isolina Santiago-Pérez; Mercedes Treviño; Rafaela Dopazo; Angelina Cañizares; Isolina Bonacho; Matilde Trigo; M Eva Fernández; Ana Cid; David Gómez; Patricia Ordóñez; Amparo Coira; M J Armada; Magdalena Porto; Sonia Perez; Alberto Malvar-Pintos Journal: PLoS One Date: 2018-08-03 Impact factor: 3.240